Martin Babler - Net Worth and Insider Trading

Martin Babler Net Worth

The estimated net worth of Martin Babler is at least $6 Million dollars as of 2024-11-28. Martin Babler is the President, CEO of Principia Biopharma Inc and owns about 58,344 shares of Principia Biopharma Inc (PRNB) stock worth over $6 Million. Details can be seen in Martin Babler's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Martin Babler has not made any transactions after 2020-06-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Martin Babler

Martin Babler Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Martin Babler owns 6 companies in total, including Principia Biopharma Inc (PRNB) , Neoleukin Therapeutics Inc (NLTX) , and ZS Pharma Inc (ZSPH) among others .

Click here to see the complete history of Martin Babler’s form 4 insider trades.

Insider Ownership Summary of Martin Babler

Ticker	Comapny	Transaction Date	Type of Owner
PRNB	Principia Biopharma Inc	2020-09-28	director & President & CEO
NLTX	Neoleukin Therapeutics Inc	2020-09-08	director
ZSPH	ZS Pharma Inc	2015-12-17	director
		2008-05-22	director
		2021-07-19	director
		2021-01-06	director

Martin Babler Latest Holdings Summary

Martin Babler currently owns a total of 1 stock. Martin Babler owns 58,344 shares of Principia Biopharma Inc (PRNB) as of June 23, 2020, with a value of $6 Million.

Latest Holdings of Martin Babler

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PRNB	Principia Biopharma Inc	2020-06-23	58,344	100.05	5,837,317

Holding Weightings of Martin Babler

Martin Babler Form 4 Trading Tracker

According to the SEC Form 4 filings, Martin Babler has made a total of 3 transactions in Principia Biopharma Inc (PRNB) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Principia Biopharma Inc is the sale of 15,000 shares on June 23, 2020, which brought Martin Babler around $927,900.

Insider Trading History of Martin Babler

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Martin Babler Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Martin Babler Ownership Network

Ownership Network List of Martin Babler

No Data

Ownership Network Relation of Martin Babler

Martin Babler Owned Company Details

What does Principia Biopharma Inc do?

Who are the key executives at Principia Biopharma Inc?

Martin Babler is the director & President & CEO of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include Chief Medical Officer Dolca Thomas , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .

Principia Biopharma Inc (PRNB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Principia Biopharma Inc Insider Transactions

No Available Data

What does Neoleukin Therapeutics Inc do?

Who are the key executives at Neoleukin Therapeutics Inc?

Martin Babler is the director of Neoleukin Therapeutics Inc. Other key executives at Neoleukin Therapeutics Inc include 10 percent owner Baker Bros. Advisors Lp , Principal Accounting Officer Sean Michael Smith , and Chief Medical Officer Priti Patel .

Neoleukin Therapeutics Inc (NLTX) Insider Trades Summary

Over the past 18 months, Martin Babler made no insider transaction in Neoleukin Therapeutics Inc (NLTX). Other recent insider transactions involving Neoleukin Therapeutics Inc (NLTX) include a net purchase of 2,285,342 shares made by Baker Bros. Advisors Lp , and a net sale of 1,323 shares made by Sean Michael Smith .

In summary, during the past 3 months, insiders sold 0 shares of Neoleukin Therapeutics Inc (NLTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 66 shares of Neoleukin Therapeutics Inc (NLTX) were sold and 114,267 shares were bought by its insiders, resulting in a net purchase of 114,201 shares.

Neoleukin Therapeutics Inc (NLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Neoleukin Therapeutics Inc Insider Transactions

No Available Data

What does ZS Pharma Inc do?

Who are the key executives at ZS Pharma Inc?

Martin Babler is the director of ZS Pharma Inc. Other key executives at ZS Pharma Inc include 10 percent owner Devon Park Associates, L.p. , Chief Operating Officer D Jeffrey Keyser , and See Remarks Adam Tomasi .

ZS Pharma Inc (ZSPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ZS Pharma Inc (ZSPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ZS Pharma Inc (ZSPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ZS Pharma Inc (ZSPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

ZS Pharma Inc Insider Transactions

No Available Data

What does Infinity Pharmaceuticals Inc do?

Who are the key executives at Infinity Pharmaceuticals Inc?

Martin Babler is the director of Infinity Pharmaceuticals Inc. Other key executives at Infinity Pharmaceuticals Inc include director & President & CEO Adelene Q Perkins , Chief Scientific Officer Stephane Peluso , and Chief Medical Officer Robert Jr. Ilaria .

Infinity Pharmaceuticals Inc (INFIQ) Insider Trades Summary

Over the past 18 months, Martin Babler made no insider transaction in Infinity Pharmaceuticals Inc (INFIQ). Other recent insider transactions involving Infinity Pharmaceuticals Inc (INFIQ) include a net sale of 410,196 shares made by Adelene Q Perkins ,

In summary, during the past 3 months, insiders sold 0 shares of Infinity Pharmaceuticals Inc (INFIQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 410,196 shares of Infinity Pharmaceuticals Inc (INFIQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 410,196 shares.

Infinity Pharmaceuticals Inc (INFIQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Infinity Pharmaceuticals Inc Insider Transactions

No Available Data

What does Prelude Therapeutics Inc do?

Who are the key executives at Prelude Therapeutics Inc?

Martin Babler is the director of Prelude Therapeutics Inc. Other key executives at Prelude Therapeutics Inc include director & President & CEO Krishna Vaddi , Chief Legal Counsel & Corp Sec. Bryant David Lim , and Chief Financial Officer Laurent Chardonnet .

Prelude Therapeutics Inc (PRLD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Prelude Therapeutics Inc (PRLD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prelude Therapeutics Inc (PRLD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Prelude Therapeutics Inc (PRLD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prelude Therapeutics Inc Insider Transactions

No Available Data

What does Omega Alpha SPAC do?

Who are the key executives at Omega Alpha SPAC?

Martin Babler is the director of Omega Alpha SPAC. Other key executives at Omega Alpha SPAC include director & 10 percent owner & Chief Executive Officer Otello Stampacchia , 10 percent owner Alpha Management Omega , and Chief Scientific Officer Vincent Ossipow .

Omega Alpha SPAC (OMEG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Omega Alpha SPAC (OMEG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Omega Alpha SPAC (OMEG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Omega Alpha SPAC (OMEG)'s detailed insider trading history can be found in Insider Trading Tracker table.

Omega Alpha SPAC Insider Transactions

No Available Data

Martin Babler Mailing Address

Above is the net worth, insider trading, and ownership report for Martin Babler. You might contact Martin Babler via mailing address: C/o Infinity Pharmaceuticals, Inc., 780 Memorial Drive, Cambridge Ma 02139.

Discussions on Martin Babler

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.